nodes	percent_of_prediction	percent_of_DWPC	metapath
Bumetanide—PTGS2—urinary bladder cancer	0.305	1	CbGaD
Bumetanide—SLC22A7—Fluorouracil—urinary bladder cancer	0.0891	0.247	CbGbCtD
Bumetanide—SLC22A11—Methotrexate—urinary bladder cancer	0.0516	0.143	CbGbCtD
Bumetanide—SLC22A7—Methotrexate—urinary bladder cancer	0.0491	0.136	CbGbCtD
Bumetanide—PTGS2—Cisplatin—urinary bladder cancer	0.0435	0.12	CbGbCtD
Bumetanide—PTGS2—Etoposide—urinary bladder cancer	0.0427	0.118	CbGbCtD
Bumetanide—CFTR—vas deferens—urinary bladder cancer	0.0392	0.274	CbGeAlD
Bumetanide—SLCO1A2—Methotrexate—urinary bladder cancer	0.0344	0.0953	CbGbCtD
Bumetanide—SLC22A8—Methotrexate—urinary bladder cancer	0.03	0.083	CbGbCtD
Bumetanide—SLC22A6—Methotrexate—urinary bladder cancer	0.0209	0.0578	CbGbCtD
Bumetanide—SLC12A1—urine—urinary bladder cancer	0.00717	0.0502	CbGeAlD
Bumetanide—SLC12A4—prostate gland—urinary bladder cancer	0.00445	0.0312	CbGeAlD
Bumetanide—SLC22A8—urine—urinary bladder cancer	0.00416	0.0291	CbGeAlD
Bumetanide—CFTR—prostate gland—urinary bladder cancer	0.0035	0.0245	CbGeAlD
Bumetanide—SLC12A2—prostate gland—urinary bladder cancer	0.00307	0.0215	CbGeAlD
Bumetanide—CFTR—seminal vesicle—urinary bladder cancer	0.00296	0.0207	CbGeAlD
Bumetanide—SLC10A1—prostate gland—urinary bladder cancer	0.0029	0.0203	CbGeAlD
Bumetanide—CA14—prostate gland—urinary bladder cancer	0.00287	0.0201	CbGeAlD
Bumetanide—CA5A—female reproductive system—urinary bladder cancer	0.00283	0.0198	CbGeAlD
Bumetanide—SLC12A1—prostate gland—urinary bladder cancer	0.00257	0.018	CbGeAlD
Bumetanide—CFTR—epithelium—urinary bladder cancer	0.00257	0.018	CbGeAlD
Bumetanide—SLC10A1—seminal vesicle—urinary bladder cancer	0.00245	0.0172	CbGeAlD
Bumetanide—SLC12A4—female reproductive system—urinary bladder cancer	0.00243	0.017	CbGeAlD
Bumetanide—CA14—seminal vesicle—urinary bladder cancer	0.00243	0.017	CbGeAlD
Bumetanide—CFTR—renal system—urinary bladder cancer	0.00238	0.0167	CbGeAlD
Bumetanide—CA7—renal system—urinary bladder cancer	0.00235	0.0164	CbGeAlD
Bumetanide—SLC12A2—epithelium—urinary bladder cancer	0.00226	0.0158	CbGeAlD
Bumetanide—SLC12A2—renal system—urinary bladder cancer	0.00209	0.0147	CbGeAlD
Bumetanide—SLC12A2—urethra—urinary bladder cancer	0.00206	0.0144	CbGeAlD
Bumetanide—CA5B—prostate gland—urinary bladder cancer	0.00201	0.014	CbGeAlD
Bumetanide—SLC10A1—renal system—urinary bladder cancer	0.00198	0.0138	CbGeAlD
Bumetanide—CFTR—female reproductive system—urinary bladder cancer	0.00191	0.0134	CbGeAlD
Bumetanide—SLC12A1—epithelium—urinary bladder cancer	0.00189	0.0132	CbGeAlD
Bumetanide—SLC22A11—renal system—urinary bladder cancer	0.00181	0.0126	CbGeAlD
Bumetanide—SLC22A7—renal system—urinary bladder cancer	0.00176	0.0123	CbGeAlD
Bumetanide—SLC12A1—renal system—urinary bladder cancer	0.00176	0.0123	CbGeAlD
Bumetanide—SLC12A1—urethra—urinary bladder cancer	0.00172	0.0121	CbGeAlD
Bumetanide—SLC12A2—female reproductive system—urinary bladder cancer	0.00168	0.0117	CbGeAlD
Bumetanide—CA9—female reproductive system—urinary bladder cancer	0.00165	0.0116	CbGeAlD
Bumetanide—SLC10A1—female reproductive system—urinary bladder cancer	0.00158	0.0111	CbGeAlD
Bumetanide—CA12—renal system—urinary bladder cancer	0.00152	0.0107	CbGeAlD
Bumetanide—SLC12A2—vagina—urinary bladder cancer	0.00152	0.0106	CbGeAlD
Bumetanide—SLC22A8—prostate gland—urinary bladder cancer	0.00149	0.0105	CbGeAlD
Bumetanide—SLC22A11—female reproductive system—urinary bladder cancer	0.00145	0.0101	CbGeAlD
Bumetanide—SLC12A4—lymph node—urinary bladder cancer	0.00142	0.00995	CbGeAlD
Bumetanide—CA4—prostate gland—urinary bladder cancer	0.00139	0.00969	CbGeAlD
Bumetanide—CA5B—urethra—urinary bladder cancer	0.00134	0.0094	CbGeAlD
Bumetanide—Hearing impaired—Thiotepa—urinary bladder cancer	0.00129	0.00983	CcSEcCtD
Bumetanide—Blood uric acid increased—Thiotepa—urinary bladder cancer	0.00125	0.00953	CcSEcCtD
Bumetanide—CA12—female reproductive system—urinary bladder cancer	0.00122	0.00855	CbGeAlD
Bumetanide—CA4—seminal vesicle—urinary bladder cancer	0.00117	0.0082	CbGeAlD
Bumetanide—Liver injury—Cisplatin—urinary bladder cancer	0.00115	0.00872	CcSEcCtD
Bumetanide—CA5B—female reproductive system—urinary bladder cancer	0.0011	0.00767	CbGeAlD
Bumetanide—Hearing impaired—Gemcitabine—urinary bladder cancer	0.00109	0.00827	CcSEcCtD
Bumetanide—SLCO1A2—renal system—urinary bladder cancer	0.00107	0.00747	CbGeAlD
Bumetanide—Hyperuricaemia—Cisplatin—urinary bladder cancer	0.00104	0.00791	CcSEcCtD
Bumetanide—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.00104	0.00788	CcSEcCtD
Bumetanide—SLC22A8—renal system—urinary bladder cancer	0.00102	0.00713	CbGeAlD
Bumetanide—Hearing impaired—Cisplatin—urinary bladder cancer	0.00101	0.00771	CcSEcCtD
Bumetanide—Abdominal pain—Valrubicin—urinary bladder cancer	0.001	0.00762	CcSEcCtD
Bumetanide—Azotaemia—Methotrexate—urinary bladder cancer	0.000994	0.00756	CcSEcCtD
Bumetanide—CA5B—vagina—urinary bladder cancer	0.000991	0.00693	CbGeAlD
Bumetanide—Blood uric acid increased—Cisplatin—urinary bladder cancer	0.000983	0.00747	CcSEcCtD
Bumetanide—SLC12A2—lymph node—urinary bladder cancer	0.000981	0.00686	CbGeAlD
Bumetanide—Hepatocellular injury—Cisplatin—urinary bladder cancer	0.000965	0.00734	CcSEcCtD
Bumetanide—Leukopenia—Mitomycin—urinary bladder cancer	0.000958	0.00728	CcSEcCtD
Bumetanide—Hyperuricaemia—Etoposide—urinary bladder cancer	0.000953	0.00725	CcSEcCtD
Bumetanide—CA4—renal system—urinary bladder cancer	0.000944	0.00661	CbGeAlD
Bumetanide—CA4—urethra—urinary bladder cancer	0.000927	0.00649	CbGeAlD
Bumetanide—Asthenia—Valrubicin—urinary bladder cancer	0.00091	0.00692	CcSEcCtD
Bumetanide—Blood uric acid increased—Etoposide—urinary bladder cancer	0.000901	0.00685	CcSEcCtD
Bumetanide—Pruritus—Valrubicin—urinary bladder cancer	0.000897	0.00682	CcSEcCtD
Bumetanide—Diarrhoea—Valrubicin—urinary bladder cancer	0.000868	0.0066	CcSEcCtD
Bumetanide—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.000855	0.0065	CcSEcCtD
Bumetanide—PTGS2—prostate gland—urinary bladder cancer	0.000848	0.00593	CbGeAlD
Bumetanide—Dizziness—Valrubicin—urinary bladder cancer	0.000838	0.00637	CcSEcCtD
Bumetanide—Blood creatinine increased—Thiotepa—urinary bladder cancer	0.000837	0.00637	CcSEcCtD
Bumetanide—Dehydration—Thiotepa—urinary bladder cancer	0.000831	0.00632	CcSEcCtD
Bumetanide—Encephalopathy—Methotrexate—urinary bladder cancer	0.000825	0.00627	CcSEcCtD
Bumetanide—Vomiting—Valrubicin—urinary bladder cancer	0.000806	0.00613	CcSEcCtD
Bumetanide—Serum creatinine increased—Epirubicin—urinary bladder cancer	0.000806	0.00613	CcSEcCtD
Bumetanide—Rash—Valrubicin—urinary bladder cancer	0.000799	0.00608	CcSEcCtD
Bumetanide—Dermatitis—Valrubicin—urinary bladder cancer	0.000799	0.00607	CcSEcCtD
Bumetanide—Polyuria—Cisplatin—urinary bladder cancer	0.000798	0.00607	CcSEcCtD
Bumetanide—Headache—Valrubicin—urinary bladder cancer	0.000794	0.00604	CcSEcCtD
Bumetanide—CA4—female reproductive system—urinary bladder cancer	0.000756	0.00529	CbGeAlD
Bumetanide—Nausea—Valrubicin—urinary bladder cancer	0.000753	0.00573	CcSEcCtD
Bumetanide—Fatigue—Mitomycin—urinary bladder cancer	0.000753	0.00573	CcSEcCtD
Bumetanide—Serum creatinine increased—Doxorubicin—urinary bladder cancer	0.000746	0.00567	CcSEcCtD
Bumetanide—Hyperventilation—Epirubicin—urinary bladder cancer	0.00072	0.00548	CcSEcCtD
Bumetanide—PTGS2—seminal vesicle—urinary bladder cancer	0.000717	0.00502	CbGeAlD
Bumetanide—Blood creatinine increased—Gemcitabine—urinary bladder cancer	0.000704	0.00536	CcSEcCtD
Bumetanide—Hyponatraemia—Cisplatin—urinary bladder cancer	0.000704	0.00535	CcSEcCtD
Bumetanide—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.000697	0.0053	CcSEcCtD
Bumetanide—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.000684	0.0052	CcSEcCtD
Bumetanide—Renal failure—Thiotepa—urinary bladder cancer	0.000677	0.00515	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.000677	0.00515	CcSEcCtD
Bumetanide—Hyperventilation—Doxorubicin—urinary bladder cancer	0.000667	0.00507	CcSEcCtD
Bumetanide—Blood creatinine increased—Cisplatin—urinary bladder cancer	0.000657	0.00499	CcSEcCtD
Bumetanide—Dehydration—Cisplatin—urinary bladder cancer	0.000652	0.00496	CcSEcCtD
Bumetanide—CA5B—lymph node—urinary bladder cancer	0.000641	0.00448	CbGeAlD
Bumetanide—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000638	0.00485	CcSEcCtD
Bumetanide—Cramp muscle—Cisplatin—urinary bladder cancer	0.000631	0.0048	CcSEcCtD
Bumetanide—Asthenia—Mitomycin—urinary bladder cancer	0.000627	0.00477	CcSEcCtD
Bumetanide—PTGS2—epithelium—urinary bladder cancer	0.000623	0.00436	CbGeAlD
Bumetanide—Glycosuria—Epirubicin—urinary bladder cancer	0.000612	0.00465	CcSEcCtD
Bumetanide—PTGS2—smooth muscle tissue—urinary bladder cancer	0.0006	0.0042	CbGeAlD
Bumetanide—Diarrhoea—Mitomycin—urinary bladder cancer	0.000598	0.00454	CcSEcCtD
Bumetanide—Pancreatitis—Cisplatin—urinary bladder cancer	0.000594	0.00451	CcSEcCtD
Bumetanide—Blood disorder—Epirubicin—urinary bladder cancer	0.000594	0.00451	CcSEcCtD
Bumetanide—Liver injury—Epirubicin—urinary bladder cancer	0.000589	0.00448	CcSEcCtD
Bumetanide—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.000586	0.00446	CcSEcCtD
Bumetanide—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.000581	0.00441	CcSEcCtD
Bumetanide—Cramp muscle—Etoposide—urinary bladder cancer	0.000578	0.0044	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000578	0.0044	CcSEcCtD
Bumetanide—PTGS2—renal system—urinary bladder cancer	0.000578	0.00404	CbGeAlD
Bumetanide—Dizziness—Mitomycin—urinary bladder cancer	0.000578	0.00439	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.000574	0.00437	CcSEcCtD
Bumetanide—Hyperuricaemia—Methotrexate—urinary bladder cancer	0.000571	0.00434	CcSEcCtD
Bumetanide—Renal failure—Gemcitabine—urinary bladder cancer	0.00057	0.00433	CcSEcCtD
Bumetanide—PTGS2—urethra—urinary bladder cancer	0.000568	0.00397	CbGeAlD
Bumetanide—Glycosuria—Doxorubicin—urinary bladder cancer	0.000566	0.00431	CcSEcCtD
Bumetanide—Sweating—Gemcitabine—urinary bladder cancer	0.000555	0.00422	CcSEcCtD
Bumetanide—Vomiting—Mitomycin—urinary bladder cancer	0.000555	0.00422	CcSEcCtD
Bumetanide—Rash—Mitomycin—urinary bladder cancer	0.000551	0.00419	CcSEcCtD
Bumetanide—Dermatitis—Mitomycin—urinary bladder cancer	0.00055	0.00418	CcSEcCtD
Bumetanide—Blood disorder—Doxorubicin—urinary bladder cancer	0.000549	0.00418	CcSEcCtD
Bumetanide—Headache—Mitomycin—urinary bladder cancer	0.000547	0.00416	CcSEcCtD
Bumetanide—Liver injury—Doxorubicin—urinary bladder cancer	0.000545	0.00414	CcSEcCtD
Bumetanide—Blood uric acid increased—Methotrexate—urinary bladder cancer	0.000539	0.0041	CcSEcCtD
Bumetanide—Hyperuricaemia—Epirubicin—urinary bladder cancer	0.000534	0.00406	CcSEcCtD
Bumetanide—Renal failure—Cisplatin—urinary bladder cancer	0.000531	0.00404	CcSEcCtD
Bumetanide—Nausea—Mitomycin—urinary bladder cancer	0.000519	0.00394	CcSEcCtD
Bumetanide—Blood uric acid increased—Epirubicin—urinary bladder cancer	0.000505	0.00384	CcSEcCtD
Bumetanide—Musculoskeletal pain—Epirubicin—urinary bladder cancer	0.000502	0.00382	CcSEcCtD
Bumetanide—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.000496	0.00377	CcSEcCtD
Bumetanide—Hyperuricaemia—Doxorubicin—urinary bladder cancer	0.000494	0.00376	CcSEcCtD
Bumetanide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000492	0.00374	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00049	0.00373	CcSEcCtD
Bumetanide—Renal failure—Etoposide—urinary bladder cancer	0.000486	0.0037	CcSEcCtD
Bumetanide—Leukopenia—Thiotepa—urinary bladder cancer	0.000482	0.00366	CcSEcCtD
Bumetanide—Gynaecomastia—Methotrexate—urinary bladder cancer	0.000474	0.0036	CcSEcCtD
Bumetanide—Blood uric acid increased—Doxorubicin—urinary bladder cancer	0.000467	0.00355	CcSEcCtD
Bumetanide—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.000464	0.00353	CcSEcCtD
Bumetanide—PTGS2—female reproductive system—urinary bladder cancer	0.000463	0.00324	CbGeAlD
Bumetanide—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.000459	0.00349	CcSEcCtD
Bumetanide—Arthralgia—Thiotepa—urinary bladder cancer	0.000458	0.00348	CcSEcCtD
Bumetanide—CA4—lymph node—urinary bladder cancer	0.000442	0.0031	CbGeAlD
Bumetanide—Polyuria—Methotrexate—urinary bladder cancer	0.000438	0.00333	CcSEcCtD
Bumetanide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00043	0.00327	CcSEcCtD
Bumetanide—Erythema multiforme—Etoposide—urinary bladder cancer	0.00042	0.00319	CcSEcCtD
Bumetanide—PTGS2—vagina—urinary bladder cancer	0.000419	0.00293	CbGeAlD
Bumetanide—Muscle spasms—Cisplatin—urinary bladder cancer	0.000406	0.00308	CcSEcCtD
Bumetanide—Leukopenia—Gemcitabine—urinary bladder cancer	0.000405	0.00308	CcSEcCtD
Bumetanide—Leukopenia—Fluorouracil—urinary bladder cancer	0.000398	0.00303	CcSEcCtD
Bumetanide—Arthralgia—Gemcitabine—urinary bladder cancer	0.000385	0.00293	CcSEcCtD
Bumetanide—Chest pain—Gemcitabine—urinary bladder cancer	0.000385	0.00293	CcSEcCtD
Bumetanide—Chest pain—Fluorouracil—urinary bladder cancer	0.000379	0.00288	CcSEcCtD
Bumetanide—Fatigue—Thiotepa—urinary bladder cancer	0.000379	0.00288	CcSEcCtD
Bumetanide—Leukopenia—Cisplatin—urinary bladder cancer	0.000378	0.00287	CcSEcCtD
Bumetanide—Muscle spasms—Etoposide—urinary bladder cancer	0.000372	0.00283	CcSEcCtD
Bumetanide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000362	0.00275	CcSEcCtD
Bumetanide—Hyponatraemia—Epirubicin—urinary bladder cancer	0.000361	0.00275	CcSEcCtD
Bumetanide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000359	0.00273	CcSEcCtD
Bumetanide—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000357	0.00272	CcSEcCtD
Bumetanide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000356	0.0027	CcSEcCtD
Bumetanide—Urticaria—Thiotepa—urinary bladder cancer	0.000349	0.00265	CcSEcCtD
Bumetanide—Vertigo—Etoposide—urinary bladder cancer	0.000347	0.00264	CcSEcCtD
Bumetanide—Abdominal pain—Thiotepa—urinary bladder cancer	0.000347	0.00264	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000346	0.00263	CcSEcCtD
Bumetanide—Leukopenia—Etoposide—urinary bladder cancer	0.000346	0.00263	CcSEcCtD
Bumetanide—Hypotension—Gemcitabine—urinary bladder cancer	0.000345	0.00263	CcSEcCtD
Bumetanide—Hypotension—Fluorouracil—urinary bladder cancer	0.000339	0.00258	CcSEcCtD
Bumetanide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000337	0.00256	CcSEcCtD
Bumetanide—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000337	0.00256	CcSEcCtD
Bumetanide—Dehydration—Epirubicin—urinary bladder cancer	0.000335	0.00254	CcSEcCtD
Bumetanide—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000334	0.00254	CcSEcCtD
Bumetanide—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000333	0.00253	CcSEcCtD
Bumetanide—Chest pain—Etoposide—urinary bladder cancer	0.000329	0.0025	CcSEcCtD
Bumetanide—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000328	0.00249	CcSEcCtD
Bumetanide—Pancreatitis—Methotrexate—urinary bladder cancer	0.000326	0.00248	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000324	0.00246	CcSEcCtD
Bumetanide—Hypotension—Cisplatin—urinary bladder cancer	0.000322	0.00245	CcSEcCtD
Bumetanide—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000319	0.00242	CcSEcCtD
Bumetanide—Fatigue—Gemcitabine—urinary bladder cancer	0.000319	0.00242	CcSEcCtD
Bumetanide—Asthenia—Thiotepa—urinary bladder cancer	0.000315	0.0024	CcSEcCtD
Bumetanide—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000312	0.00237	CcSEcCtD
Bumetanide—Pruritus—Thiotepa—urinary bladder cancer	0.000311	0.00236	CcSEcCtD
Bumetanide—Dehydration—Doxorubicin—urinary bladder cancer	0.00031	0.00235	CcSEcCtD
Bumetanide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000309	0.00235	CcSEcCtD
Bumetanide—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000305	0.00232	CcSEcCtD
Bumetanide—Pancreatitis—Epirubicin—urinary bladder cancer	0.000305	0.00232	CcSEcCtD
Bumetanide—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000303	0.0023	CcSEcCtD
Bumetanide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000301	0.00229	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.0003	0.00228	CcSEcCtD
Bumetanide—Hypotension—Etoposide—urinary bladder cancer	0.000295	0.00224	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000294	0.00223	CcSEcCtD
Bumetanide—Renal failure—Methotrexate—urinary bladder cancer	0.000291	0.00221	CcSEcCtD
Bumetanide—Dizziness—Thiotepa—urinary bladder cancer	0.00029	0.00221	CcSEcCtD
Bumetanide—Urticaria—Fluorouracil—urinary bladder cancer	0.000289	0.00219	CcSEcCtD
Bumetanide—Sweating—Methotrexate—urinary bladder cancer	0.000284	0.00216	CcSEcCtD
Bumetanide—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000282	0.00215	CcSEcCtD
Bumetanide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000281	0.00213	CcSEcCtD
Bumetanide—Vomiting—Thiotepa—urinary bladder cancer	0.000279	0.00212	CcSEcCtD
Bumetanide—Rash—Thiotepa—urinary bladder cancer	0.000277	0.00211	CcSEcCtD
Bumetanide—Dermatitis—Thiotepa—urinary bladder cancer	0.000277	0.0021	CcSEcCtD
Bumetanide—Headache—Thiotepa—urinary bladder cancer	0.000275	0.00209	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000275	0.00209	CcSEcCtD
Bumetanide—Renal failure—Epirubicin—urinary bladder cancer	0.000273	0.00207	CcSEcCtD
Bumetanide—Fatigue—Etoposide—urinary bladder cancer	0.000272	0.00207	CcSEcCtD
Bumetanide—PTGS2—lymph node—urinary bladder cancer	0.000271	0.0019	CbGeAlD
Bumetanide—Sweating—Epirubicin—urinary bladder cancer	0.000266	0.00202	CcSEcCtD
Bumetanide—Asthenia—Gemcitabine—urinary bladder cancer	0.000265	0.00202	CcSEcCtD
Bumetanide—Pruritus—Gemcitabine—urinary bladder cancer	0.000261	0.00199	CcSEcCtD
Bumetanide—Nausea—Thiotepa—urinary bladder cancer	0.000261	0.00198	CcSEcCtD
Bumetanide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00026	0.00197	CcSEcCtD
Bumetanide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000258	0.00196	CcSEcCtD
Bumetanide—Pruritus—Fluorouracil—urinary bladder cancer	0.000257	0.00195	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000254	0.00193	CcSEcCtD
Bumetanide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000253	0.00192	CcSEcCtD
Bumetanide—Renal failure—Doxorubicin—urinary bladder cancer	0.000252	0.00192	CcSEcCtD
Bumetanide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000252	0.00191	CcSEcCtD
Bumetanide—Urticaria—Etoposide—urinary bladder cancer	0.000251	0.00191	CcSEcCtD
Bumetanide—Abdominal pain—Etoposide—urinary bladder cancer	0.000249	0.0019	CcSEcCtD
Bumetanide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000249	0.00189	CcSEcCtD
Bumetanide—Asthenia—Cisplatin—urinary bladder cancer	0.000247	0.00188	CcSEcCtD
Bumetanide—Sweating—Doxorubicin—urinary bladder cancer	0.000246	0.00187	CcSEcCtD
Bumetanide—Dizziness—Fluorouracil—urinary bladder cancer	0.00024	0.00183	CcSEcCtD
Bumetanide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000236	0.00179	CcSEcCtD
Bumetanide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000235	0.00179	CcSEcCtD
Bumetanide—Vomiting—Gemcitabine—urinary bladder cancer	0.000235	0.00179	CcSEcCtD
Bumetanide—Rash—Gemcitabine—urinary bladder cancer	0.000233	0.00177	CcSEcCtD
Bumetanide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000233	0.00177	CcSEcCtD
Bumetanide—Headache—Gemcitabine—urinary bladder cancer	0.000231	0.00176	CcSEcCtD
Bumetanide—Vomiting—Fluorouracil—urinary bladder cancer	0.000231	0.00176	CcSEcCtD
Bumetanide—Rash—Fluorouracil—urinary bladder cancer	0.000229	0.00174	CcSEcCtD
Bumetanide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000229	0.00174	CcSEcCtD
Bumetanide—Headache—Fluorouracil—urinary bladder cancer	0.000228	0.00173	CcSEcCtD
Bumetanide—Asthenia—Etoposide—urinary bladder cancer	0.000226	0.00172	CcSEcCtD
Bumetanide—Pruritus—Etoposide—urinary bladder cancer	0.000223	0.0017	CcSEcCtD
Bumetanide—Nausea—Gemcitabine—urinary bladder cancer	0.000219	0.00167	CcSEcCtD
Bumetanide—Vomiting—Cisplatin—urinary bladder cancer	0.000219	0.00167	CcSEcCtD
Bumetanide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000218	0.00166	CcSEcCtD
Bumetanide—Rash—Cisplatin—urinary bladder cancer	0.000217	0.00165	CcSEcCtD
Bumetanide—Dermatitis—Cisplatin—urinary bladder cancer	0.000217	0.00165	CcSEcCtD
Bumetanide—Diarrhoea—Etoposide—urinary bladder cancer	0.000216	0.00164	CcSEcCtD
Bumetanide—Nausea—Fluorouracil—urinary bladder cancer	0.000216	0.00164	CcSEcCtD
Bumetanide—Dizziness—Etoposide—urinary bladder cancer	0.000209	0.00159	CcSEcCtD
Bumetanide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000208	0.00158	CcSEcCtD
Bumetanide—Vertigo—Methotrexate—urinary bladder cancer	0.000208	0.00158	CcSEcCtD
Bumetanide—Leukopenia—Methotrexate—urinary bladder cancer	0.000207	0.00158	CcSEcCtD
Bumetanide—Nausea—Cisplatin—urinary bladder cancer	0.000205	0.00156	CcSEcCtD
Bumetanide—Vomiting—Etoposide—urinary bladder cancer	0.000201	0.00153	CcSEcCtD
Bumetanide—Rash—Etoposide—urinary bladder cancer	0.000199	0.00151	CcSEcCtD
Bumetanide—Dermatitis—Etoposide—urinary bladder cancer	0.000199	0.00151	CcSEcCtD
Bumetanide—Headache—Etoposide—urinary bladder cancer	0.000198	0.0015	CcSEcCtD
Bumetanide—Arthralgia—Methotrexate—urinary bladder cancer	0.000197	0.0015	CcSEcCtD
Bumetanide—Chest pain—Methotrexate—urinary bladder cancer	0.000197	0.0015	CcSEcCtD
Bumetanide—Vertigo—Epirubicin—urinary bladder cancer	0.000195	0.00148	CcSEcCtD
Bumetanide—Leukopenia—Epirubicin—urinary bladder cancer	0.000194	0.00147	CcSEcCtD
Bumetanide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000193	0.00147	CcSEcCtD
Bumetanide—Nausea—Etoposide—urinary bladder cancer	0.000187	0.00143	CcSEcCtD
Bumetanide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000185	0.00141	CcSEcCtD
Bumetanide—Chest pain—Epirubicin—urinary bladder cancer	0.000185	0.0014	CcSEcCtD
Bumetanide—Arthralgia—Epirubicin—urinary bladder cancer	0.000185	0.0014	CcSEcCtD
Bumetanide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000183	0.00139	CcSEcCtD
Bumetanide—Dry mouth—Epirubicin—urinary bladder cancer	0.00018	0.00137	CcSEcCtD
Bumetanide—Vertigo—Doxorubicin—urinary bladder cancer	0.00018	0.00137	CcSEcCtD
Bumetanide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000179	0.00136	CcSEcCtD
Bumetanide—Hypotension—Methotrexate—urinary bladder cancer	0.000177	0.00134	CcSEcCtD
Bumetanide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000173	0.00132	CcSEcCtD
Bumetanide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000171	0.0013	CcSEcCtD
Bumetanide—Chest pain—Doxorubicin—urinary bladder cancer	0.000171	0.0013	CcSEcCtD
Bumetanide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000171	0.0013	CcSEcCtD
Bumetanide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000167	0.00127	CcSEcCtD
Bumetanide—Hypotension—Epirubicin—urinary bladder cancer	0.000165	0.00126	CcSEcCtD
Bumetanide—Fatigue—Methotrexate—urinary bladder cancer	0.000163	0.00124	CcSEcCtD
Bumetanide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00016	0.00122	CcSEcCtD
Bumetanide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000158	0.0012	CcSEcCtD
Bumetanide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000155	0.00118	CcSEcCtD
Bumetanide—Hypotension—Doxorubicin—urinary bladder cancer	0.000153	0.00116	CcSEcCtD
Bumetanide—Fatigue—Epirubicin—urinary bladder cancer	0.000152	0.00116	CcSEcCtD
Bumetanide—Urticaria—Methotrexate—urinary bladder cancer	0.00015	0.00114	CcSEcCtD
Bumetanide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000149	0.00114	CcSEcCtD
Bumetanide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000145	0.0011	CcSEcCtD
Bumetanide—Fatigue—Doxorubicin—urinary bladder cancer	0.000141	0.00107	CcSEcCtD
Bumetanide—Urticaria—Epirubicin—urinary bladder cancer	0.000141	0.00107	CcSEcCtD
Bumetanide—Abdominal pain—Epirubicin—urinary bladder cancer	0.00014	0.00106	CcSEcCtD
Bumetanide—Asthenia—Methotrexate—urinary bladder cancer	0.000136	0.00103	CcSEcCtD
Bumetanide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000134	0.00102	CcSEcCtD
Bumetanide—Pruritus—Methotrexate—urinary bladder cancer	0.000134	0.00102	CcSEcCtD
Bumetanide—Urticaria—Doxorubicin—urinary bladder cancer	0.00013	0.000989	CcSEcCtD
Bumetanide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000129	0.000984	CcSEcCtD
Bumetanide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000129	0.000983	CcSEcCtD
Bumetanide—Asthenia—Epirubicin—urinary bladder cancer	0.000127	0.000965	CcSEcCtD
Bumetanide—Pruritus—Epirubicin—urinary bladder cancer	0.000125	0.000951	CcSEcCtD
Bumetanide—Dizziness—Methotrexate—urinary bladder cancer	0.000125	0.00095	CcSEcCtD
Bumetanide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000121	0.00092	CcSEcCtD
Bumetanide—Vomiting—Methotrexate—urinary bladder cancer	0.00012	0.000914	CcSEcCtD
Bumetanide—Rash—Methotrexate—urinary bladder cancer	0.000119	0.000906	CcSEcCtD
Bumetanide—Dermatitis—Methotrexate—urinary bladder cancer	0.000119	0.000905	CcSEcCtD
Bumetanide—Headache—Methotrexate—urinary bladder cancer	0.000118	0.0009	CcSEcCtD
Bumetanide—Asthenia—Doxorubicin—urinary bladder cancer	0.000117	0.000893	CcSEcCtD
Bumetanide—Dizziness—Epirubicin—urinary bladder cancer	0.000117	0.000889	CcSEcCtD
Bumetanide—Pruritus—Doxorubicin—urinary bladder cancer	0.000116	0.00088	CcSEcCtD
Bumetanide—Vomiting—Epirubicin—urinary bladder cancer	0.000112	0.000855	CcSEcCtD
Bumetanide—Nausea—Methotrexate—urinary bladder cancer	0.000112	0.000854	CcSEcCtD
Bumetanide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000112	0.000851	CcSEcCtD
Bumetanide—Rash—Epirubicin—urinary bladder cancer	0.000112	0.000848	CcSEcCtD
Bumetanide—Dermatitis—Epirubicin—urinary bladder cancer	0.000111	0.000847	CcSEcCtD
Bumetanide—Headache—Epirubicin—urinary bladder cancer	0.000111	0.000842	CcSEcCtD
Bumetanide—Dizziness—Doxorubicin—urinary bladder cancer	0.000108	0.000823	CcSEcCtD
Bumetanide—Nausea—Epirubicin—urinary bladder cancer	0.000105	0.000799	CcSEcCtD
Bumetanide—Vomiting—Doxorubicin—urinary bladder cancer	0.000104	0.000791	CcSEcCtD
Bumetanide—Rash—Doxorubicin—urinary bladder cancer	0.000103	0.000785	CcSEcCtD
Bumetanide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000103	0.000784	CcSEcCtD
Bumetanide—Headache—Doxorubicin—urinary bladder cancer	0.000103	0.00078	CcSEcCtD
Bumetanide—Nausea—Doxorubicin—urinary bladder cancer	9.72e-05	0.000739	CcSEcCtD
Bumetanide—CA4—Metabolism—RRM2—urinary bladder cancer	5.82e-05	0.000986	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—UGT2B7—urinary bladder cancer	5.8e-05	0.000983	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.74e-05	0.000973	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—HPGDS—urinary bladder cancer	5.65e-05	0.000957	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—ENO2—urinary bladder cancer	5.65e-05	0.000957	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.64e-05	0.000956	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	5.62e-05	0.000953	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.61e-05	0.000951	CbGpPWpGaD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	5.59e-05	0.000947	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—CDKN1A—urinary bladder cancer	5.5e-05	0.000932	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	5.48e-05	0.000928	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—GSTT1—urinary bladder cancer	5.48e-05	0.000928	CbGpPWpGaD
Bumetanide—CA12—Metabolism—NQO1—urinary bladder cancer	5.44e-05	0.000923	CbGpPWpGaD
Bumetanide—CA9—Metabolism—NAT2—urinary bladder cancer	5.44e-05	0.000923	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.39e-05	0.000914	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.39e-05	0.000914	CbGpPWpGaD
Bumetanide—CA14—Metabolism—GSTP1—urinary bladder cancer	5.39e-05	0.000913	CbGpPWpGaD
Bumetanide—CA4—Metabolism—HPGDS—urinary bladder cancer	5.39e-05	0.000913	CbGpPWpGaD
Bumetanide—CA4—Metabolism—ENO2—urinary bladder cancer	5.39e-05	0.000913	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	5.3e-05	0.000898	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—GSTP1—urinary bladder cancer	5.25e-05	0.00089	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—EP300—urinary bladder cancer	5.23e-05	0.000887	CbGpPWpGaD
Bumetanide—CA4—Metabolism—GSTT1—urinary bladder cancer	5.22e-05	0.000886	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CYP4B1—urinary bladder cancer	5.22e-05	0.000885	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	5.1e-05	0.000865	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.07e-05	0.000859	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	5.04e-05	0.000855	CbGpPWpGaD
Bumetanide—CA14—Metabolism—TYMS—urinary bladder cancer	5.01e-05	0.000849	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5e-05	0.000847	CbGpPWpGaD
Bumetanide—CA14—Metabolism—NCOR1—urinary bladder cancer	4.95e-05	0.000839	CbGpPWpGaD
Bumetanide—CA14—Metabolism—GSTM1—urinary bladder cancer	4.95e-05	0.000839	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—SLC19A1—urinary bladder cancer	4.93e-05	0.000836	CbGpPWpGaD
Bumetanide—CA7—Metabolism—GSTP1—urinary bladder cancer	4.9e-05	0.000831	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—GSTP1—urinary bladder cancer	4.9e-05	0.000831	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—TYMS—urinary bladder cancer	4.88e-05	0.000827	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—NCOR1—urinary bladder cancer	4.82e-05	0.000818	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—GSTM1—urinary bladder cancer	4.82e-05	0.000818	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PRSS3—urinary bladder cancer	4.81e-05	0.000815	CbGpPWpGaD
Bumetanide—CA14—Metabolism—GPX1—urinary bladder cancer	4.74e-05	0.000804	CbGpPWpGaD
Bumetanide—CA9—Metabolism—RRM2—urinary bladder cancer	4.7e-05	0.000797	CbGpPWpGaD
Bumetanide—CA14—Metabolism—ERCC2—urinary bladder cancer	4.65e-05	0.000789	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—GPX1—urinary bladder cancer	4.62e-05	0.000783	CbGpPWpGaD
Bumetanide—PTGS2—Disease—GSTO2—urinary bladder cancer	4.57e-05	0.000775	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—TYMS—urinary bladder cancer	4.56e-05	0.000772	CbGpPWpGaD
Bumetanide—CA7—Metabolism—TYMS—urinary bladder cancer	4.56e-05	0.000772	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—NQO1—urinary bladder cancer	4.55e-05	0.000771	CbGpPWpGaD
Bumetanide—CA12—Metabolism—GSTP1—urinary bladder cancer	4.54e-05	0.00077	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—ERCC2—urinary bladder cancer	4.54e-05	0.000769	CbGpPWpGaD
Bumetanide—CA7—Metabolism—GSTM1—urinary bladder cancer	4.5e-05	0.000763	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—NCOR1—urinary bladder cancer	4.5e-05	0.000763	CbGpPWpGaD
Bumetanide—CA7—Metabolism—NCOR1—urinary bladder cancer	4.5e-05	0.000763	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—GSTM1—urinary bladder cancer	4.5e-05	0.000763	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	4.48e-05	0.000759	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.41e-05	0.000748	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.41e-05	0.000748	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.4e-05	0.000745	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	4.39e-05	0.000745	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.38e-05	0.000742	CbGpPWpGaD
Bumetanide—CA14—Metabolism—MTHFR—urinary bladder cancer	4.37e-05	0.000742	CbGpPWpGaD
Bumetanide—CA9—Metabolism—ENO2—urinary bladder cancer	4.35e-05	0.000738	CbGpPWpGaD
Bumetanide—CA9—Metabolism—HPGDS—urinary bladder cancer	4.35e-05	0.000738	CbGpPWpGaD
Bumetanide—CA4—Metabolism—NQO1—urinary bladder cancer	4.34e-05	0.000736	CbGpPWpGaD
Bumetanide—CA7—Metabolism—GPX1—urinary bladder cancer	4.31e-05	0.000731	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—GPX1—urinary bladder cancer	4.31e-05	0.000731	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	4.28e-05	0.000726	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—MTHFR—urinary bladder cancer	4.26e-05	0.000723	CbGpPWpGaD
Bumetanide—CA7—Metabolism—ERCC2—urinary bladder cancer	4.23e-05	0.000718	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—ERCC2—urinary bladder cancer	4.23e-05	0.000718	CbGpPWpGaD
Bumetanide—CA12—Metabolism—TYMS—urinary bladder cancer	4.22e-05	0.000716	CbGpPWpGaD
Bumetanide—CA9—Metabolism—GSTT1—urinary bladder cancer	4.22e-05	0.000716	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	4.17e-05	0.000707	CbGpPWpGaD
Bumetanide—CA12—Metabolism—NCOR1—urinary bladder cancer	4.17e-05	0.000707	CbGpPWpGaD
Bumetanide—CA12—Metabolism—GSTM1—urinary bladder cancer	4.17e-05	0.000707	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	4.06e-05	0.000688	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	4.05e-05	0.000687	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	4.04e-05	0.000685	CbGpPWpGaD
Bumetanide—CA12—Metabolism—GPX1—urinary bladder cancer	4e-05	0.000677	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—MTHFR—urinary bladder cancer	3.98e-05	0.000675	CbGpPWpGaD
Bumetanide—CA7—Metabolism—MTHFR—urinary bladder cancer	3.98e-05	0.000675	CbGpPWpGaD
Bumetanide—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	3.94e-05	0.000668	CbGpPWpGaD
Bumetanide—CA12—Metabolism—ERCC2—urinary bladder cancer	3.92e-05	0.000665	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.85e-05	0.000653	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.85e-05	0.000653	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—TYMP—urinary bladder cancer	3.84e-05	0.000651	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.84e-05	0.00065	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—GSTO2—urinary bladder cancer	3.83e-05	0.000649	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—NAT1—urinary bladder cancer	3.83e-05	0.000649	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—GSTP1—urinary bladder cancer	3.8e-05	0.000643	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.79e-05	0.000642	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.77e-05	0.000639	CbGpPWpGaD
Bumetanide—CA9—Cellular responses to stress—TP53—urinary bladder cancer	3.74e-05	0.000635	CbGpPWpGaD
Bumetanide—SLC22A11—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.72e-05	0.000631	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.69e-05	0.000626	CbGpPWpGaD
Bumetanide—CA12—Metabolism—MTHFR—urinary bladder cancer	3.69e-05	0.000625	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.67e-05	0.000623	CbGpPWpGaD
Bumetanide—CA4—Metabolism—GSTP1—urinary bladder cancer	3.62e-05	0.000614	CbGpPWpGaD
Bumetanide—PTGS2—Disease—SLC19A1—urinary bladder cancer	3.56e-05	0.000603	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PPARG—urinary bladder cancer	3.55e-05	0.000601	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—TYMS—urinary bladder cancer	3.53e-05	0.000598	CbGpPWpGaD
Bumetanide—CA9—Metabolism—NQO1—urinary bladder cancer	3.51e-05	0.000595	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	3.5e-05	0.000594	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—NCOR1—urinary bladder cancer	3.49e-05	0.000591	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—GSTM1—urinary bladder cancer	3.49e-05	0.000591	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—NAT2—urinary bladder cancer	3.47e-05	0.000589	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PRSS3—urinary bladder cancer	3.47e-05	0.000588	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PPARG—urinary bladder cancer	3.46e-05	0.000586	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	3.45e-05	0.000585	CbGpPWpGaD
Bumetanide—CA14—Metabolism—CREBBP—urinary bladder cancer	3.41e-05	0.000578	CbGpPWpGaD
Bumetanide—SLC22A7—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.38e-05	0.000573	CbGpPWpGaD
Bumetanide—CA4—Metabolism—TYMS—urinary bladder cancer	3.37e-05	0.000571	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	3.35e-05	0.000567	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—GPX1—urinary bladder cancer	3.34e-05	0.000566	CbGpPWpGaD
Bumetanide—CA4—Metabolism—GSTM1—urinary bladder cancer	3.33e-05	0.000564	CbGpPWpGaD
Bumetanide—CA4—Metabolism—NCOR1—urinary bladder cancer	3.33e-05	0.000564	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—CREBBP—urinary bladder cancer	3.32e-05	0.000563	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HDAC4—urinary bladder cancer	3.31e-05	0.00056	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—ERCC2—urinary bladder cancer	3.28e-05	0.000556	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	3.27e-05	0.000555	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PPARG—urinary bladder cancer	3.23e-05	0.000547	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PPARG—urinary bladder cancer	3.23e-05	0.000547	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.21e-05	0.000545	CbGpPWpGaD
Bumetanide—CA4—Metabolism—GPX1—urinary bladder cancer	3.19e-05	0.00054	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	3.15e-05	0.000535	CbGpPWpGaD
Bumetanide—CA4—Metabolism—ERCC2—urinary bladder cancer	3.13e-05	0.00053	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.12e-05	0.000529	CbGpPWpGaD
Bumetanide—CA7—Metabolism—CREBBP—urinary bladder cancer	3.1e-05	0.000526	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—CREBBP—urinary bladder cancer	3.1e-05	0.000526	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—MTHFR—urinary bladder cancer	3.08e-05	0.000523	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—RRM2—urinary bladder cancer	3e-05	0.000508	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PPARG—urinary bladder cancer	2.99e-05	0.000507	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	2.98e-05	0.000505	CbGpPWpGaD
Bumetanide—CA4—Metabolism—MTHFR—urinary bladder cancer	2.94e-05	0.000499	CbGpPWpGaD
Bumetanide—CA9—Metabolism—GSTP1—urinary bladder cancer	2.93e-05	0.000496	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PRSS3—urinary bladder cancer	2.9e-05	0.000492	CbGpPWpGaD
Bumetanide—CA12—Metabolism—CREBBP—urinary bladder cancer	2.87e-05	0.000487	CbGpPWpGaD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.84e-05	0.000482	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.84e-05	0.000481	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PTGS2—urinary bladder cancer	2.79e-05	0.000473	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—ENO2—urinary bladder cancer	2.78e-05	0.000471	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—HPGDS—urinary bladder cancer	2.78e-05	0.000471	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.76e-05	0.000468	CbGpPWpGaD
Bumetanide—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	2.75e-05	0.000466	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.75e-05	0.000466	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.74e-05	0.000464	CbGpPWpGaD
Bumetanide—CA9—Metabolism—TYMS—urinary bladder cancer	2.72e-05	0.000461	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PTGS2—urinary bladder cancer	2.72e-05	0.000461	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—GSTT1—urinary bladder cancer	2.69e-05	0.000457	CbGpPWpGaD
Bumetanide—CA9—Metabolism—GSTM1—urinary bladder cancer	2.69e-05	0.000456	CbGpPWpGaD
Bumetanide—CA9—Metabolism—NCOR1—urinary bladder cancer	2.69e-05	0.000456	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.65e-05	0.00045	CbGpPWpGaD
Bumetanide—PTGS2—Disease—LIG1—urinary bladder cancer	2.63e-05	0.000445	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.61e-05	0.000443	CbGpPWpGaD
Bumetanide—CA9—Metabolism—GPX1—urinary bladder cancer	2.57e-05	0.000436	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.54e-05	0.000431	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PTGS2—urinary bladder cancer	2.54e-05	0.00043	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PTGS2—urinary bladder cancer	2.54e-05	0.00043	CbGpPWpGaD
Bumetanide—CA9—Metabolism—ERCC2—urinary bladder cancer	2.53e-05	0.000429	CbGpPWpGaD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.52e-05	0.000428	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PPARG—urinary bladder cancer	2.5e-05	0.000424	CbGpPWpGaD
Bumetanide—CA14—Metabolism—PTEN—urinary bladder cancer	2.43e-05	0.000413	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—CREBBP—urinary bladder cancer	2.4e-05	0.000407	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PPARG—urinary bladder cancer	2.38e-05	0.000404	CbGpPWpGaD
Bumetanide—CA9—Metabolism—MTHFR—urinary bladder cancer	2.38e-05	0.000403	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—PTEN—urinary bladder cancer	2.37e-05	0.000402	CbGpPWpGaD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.37e-05	0.000402	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PTGS2—urinary bladder cancer	2.35e-05	0.000399	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.33e-05	0.000395	CbGpPWpGaD
Bumetanide—CA14—Metabolism—EP300—urinary bladder cancer	2.32e-05	0.000393	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.32e-05	0.000393	CbGpPWpGaD
Bumetanide—CA4—Metabolism—CREBBP—urinary bladder cancer	2.29e-05	0.000388	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.28e-05	0.000386	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—EP300—urinary bladder cancer	2.26e-05	0.000383	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—NQO1—urinary bladder cancer	2.24e-05	0.00038	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.23e-05	0.000378	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.23e-05	0.000378	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—PTEN—urinary bladder cancer	2.21e-05	0.000375	CbGpPWpGaD
Bumetanide—CA7—Metabolism—PTEN—urinary bladder cancer	2.21e-05	0.000375	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.17e-05	0.000368	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.12e-05	0.00036	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—EP300—urinary bladder cancer	2.11e-05	0.000358	CbGpPWpGaD
Bumetanide—CA7—Metabolism—EP300—urinary bladder cancer	2.11e-05	0.000358	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.1e-05	0.000357	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.1e-05	0.000356	CbGpPWpGaD
Bumetanide—CA12—Metabolism—PTEN—urinary bladder cancer	2.05e-05	0.000348	CbGpPWpGaD
Bumetanide—PTGS2—Disease—ENO2—urinary bladder cancer	2e-05	0.00034	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PTGS2—urinary bladder cancer	1.97e-05	0.000333	CbGpPWpGaD
Bumetanide—CA12—Metabolism—EP300—urinary bladder cancer	1.96e-05	0.000332	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PPARG—urinary bladder cancer	1.93e-05	0.000327	CbGpPWpGaD
Bumetanide—PTGS2—Disease—RBX1—urinary bladder cancer	1.9e-05	0.000322	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.89e-05	0.000321	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PTGS2—urinary bladder cancer	1.88e-05	0.000318	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.87e-05	0.000317	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—GSTP1—urinary bladder cancer	1.87e-05	0.000317	CbGpPWpGaD
Bumetanide—CA9—Metabolism—CREBBP—urinary bladder cancer	1.85e-05	0.000314	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.81e-05	0.000307	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.81e-05	0.000306	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—TYMS—urinary bladder cancer	1.74e-05	0.000294	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	1.72e-05	0.000291	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	1.72e-05	0.000291	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—PTEN—urinary bladder cancer	1.71e-05	0.000291	CbGpPWpGaD
Bumetanide—PTGS2—Disease—JAG1—urinary bladder cancer	1.7e-05	0.000288	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.68e-05	0.000284	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.68e-05	0.000284	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.67e-05	0.000283	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	1.64e-05	0.000279	CbGpPWpGaD
Bumetanide—CA4—Metabolism—PTEN—urinary bladder cancer	1.64e-05	0.000277	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—EP300—urinary bladder cancer	1.64e-05	0.000277	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	0.000276	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	1.61e-05	0.000274	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.6e-05	0.000272	CbGpPWpGaD
Bumetanide—CA4—Metabolism—EP300—urinary bladder cancer	1.56e-05	0.000264	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	1.52e-05	0.000257	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PTGS2—urinary bladder cancer	1.52e-05	0.000257	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.35e-05	0.000229	CbGpPWpGaD
Bumetanide—CA9—Metabolism—PTEN—urinary bladder cancer	1.32e-05	0.000224	CbGpPWpGaD
Bumetanide—CA9—Metabolism—EP300—urinary bladder cancer	1.26e-05	0.000214	CbGpPWpGaD
Bumetanide—PTGS2—Disease—NCOR1—urinary bladder cancer	1.24e-05	0.00021	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	1.23e-05	0.000208	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	1.18e-05	0.0002	CbGpPWpGaD
Bumetanide—PTGS2—Disease—ERCC2—urinary bladder cancer	1.16e-05	0.000197	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.14e-05	0.000194	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	0.000191	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MTHFR—urinary bladder cancer	1.09e-05	0.000185	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.09e-05	0.000185	CbGpPWpGaD
Bumetanide—PTGS2—Disease—TERT—urinary bladder cancer	1.09e-05	0.000185	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.05e-05	0.000178	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	0.000176	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	0.000176	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FGFR3—urinary bladder cancer	1e-05	0.00017	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—GPX1—urinary bladder cancer	9.92e-06	0.000168	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—ERCC2—urinary bladder cancer	9.74e-06	0.000165	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	9.67e-06	0.000164	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—MTHFR—urinary bladder cancer	9.16e-06	0.000155	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CREBBP—urinary bladder cancer	8.52e-06	0.000144	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	8.44e-06	0.000143	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—EP300—urinary bladder cancer	8.05e-06	0.000136	CbGpPWpGaD
Bumetanide—PTGS2—Disease—RHOA—urinary bladder cancer	7.71e-06	0.000131	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PPARG—urinary bladder cancer	7.43e-06	0.000126	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—CREBBP—urinary bladder cancer	7.13e-06	0.000121	CbGpPWpGaD
Bumetanide—PTGS2—Disease—ERBB2—urinary bladder cancer	7.13e-06	0.000121	CbGpPWpGaD
Bumetanide—PTGS2—Disease—CDKN1A—urinary bladder cancer	6.1e-06	0.000103	CbGpPWpGaD
Bumetanide—PTGS2—Disease—PTEN—urinary bladder cancer	6.08e-06	0.000103	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EP300—urinary bladder cancer	5.8e-06	9.84e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—SRC—urinary bladder cancer	5.64e-06	9.57e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—PTEN—urinary bladder cancer	5.1e-06	8.64e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—MYC—urinary bladder cancer	5.06e-06	8.57e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—EGFR—urinary bladder cancer	4.95e-06	8.38e-05	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—EP300—urinary bladder cancer	4.86e-06	8.24e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—KRAS—urinary bladder cancer	4.67e-06	7.92e-05	CbGpPWpGaD
Bumetanide—PTGS2—Disease—HRAS—urinary bladder cancer	3.97e-06	6.73e-05	CbGpPWpGaD
